In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer
© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics..
BACKGROUND: Small-cell lung cancer (SCLC) molecular subtypes have been primarily characterized based on the expression pattern of the following key transcription regulators: ASCL1 (SCLC-A), NEUROD1 (SCLC-N), POU2F3 (SCLC-P) and YAP1 (SCLC-Y). Here, we investigated the proteomic landscape of these molecular subsets with the aim to identify novel subtype-specific proteins of diagnostic and therapeutic relevance.
METHODS: Pellets and cell media of 26 human SCLC cell lines were subjected to label-free shotgun proteomics for large-scale protein identification and quantitation, followed by in-depth bioinformatic analyses. Proteomic data were correlated with the cell lines' phenotypic characteristics and with public transcriptomic data of SCLC cell lines and tissues.
RESULTS: Our quantitative proteomic data highlighted that four molecular subtypes are clearly distinguishable at the protein level. The cell lines exhibited diverse neuroendocrine and epithelial-mesenchymal characteristics that varied by subtype. A total of 367 proteins were identified in the cell pellet and 34 in the culture media that showed significant up- or downregulation in one subtype, including known druggable proteins and potential blood-based markers. Pathway enrichment analysis and parallel investigation of transcriptomics from SCLC cell lines outlined unique signatures for each subtype, such as upregulated oxidative phosphorylation in SCLC-A, DNA replication in SCLC-N, neurotrophin signalling in SCLC-P and epithelial-mesenchymal transition in SCLC-Y. Importantly, we identified the YAP1-driven subtype as the most distinct SCLC subgroup. Using sparse partial least squares discriminant analysis, we identified proteins that clearly distinguish four SCLC subtypes based on their expression pattern, including potential diagnostic markers for SCLC-Y (e.g. GPX8, PKD2 and UFO).
CONCLUSIONS: We report for the first time, the protein expression differences among SCLC subtypes. By shedding light on potential subtype-specific therapeutic vulnerabilities and diagnostic biomarkers, our results may contribute to a better understanding of SCLC biology and the development of novel therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical and translational medicine - 12(2022), 9 vom: 18. Sept., Seite e1060 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Szeitz, Beáta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2022 Date Revised 01.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/ctm2.1060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346661277 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346661277 | ||
| 003 | DE-627 | ||
| 005 | 20231226032002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ctm2.1060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346661277 | ||
| 035 | |a (NLM)36149789 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Szeitz, Beáta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2022 | ||
| 500 | |a Date Revised 01.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. | ||
| 520 | |a BACKGROUND: Small-cell lung cancer (SCLC) molecular subtypes have been primarily characterized based on the expression pattern of the following key transcription regulators: ASCL1 (SCLC-A), NEUROD1 (SCLC-N), POU2F3 (SCLC-P) and YAP1 (SCLC-Y). Here, we investigated the proteomic landscape of these molecular subsets with the aim to identify novel subtype-specific proteins of diagnostic and therapeutic relevance | ||
| 520 | |a METHODS: Pellets and cell media of 26 human SCLC cell lines were subjected to label-free shotgun proteomics for large-scale protein identification and quantitation, followed by in-depth bioinformatic analyses. Proteomic data were correlated with the cell lines' phenotypic characteristics and with public transcriptomic data of SCLC cell lines and tissues | ||
| 520 | |a RESULTS: Our quantitative proteomic data highlighted that four molecular subtypes are clearly distinguishable at the protein level. The cell lines exhibited diverse neuroendocrine and epithelial-mesenchymal characteristics that varied by subtype. A total of 367 proteins were identified in the cell pellet and 34 in the culture media that showed significant up- or downregulation in one subtype, including known druggable proteins and potential blood-based markers. Pathway enrichment analysis and parallel investigation of transcriptomics from SCLC cell lines outlined unique signatures for each subtype, such as upregulated oxidative phosphorylation in SCLC-A, DNA replication in SCLC-N, neurotrophin signalling in SCLC-P and epithelial-mesenchymal transition in SCLC-Y. Importantly, we identified the YAP1-driven subtype as the most distinct SCLC subgroup. Using sparse partial least squares discriminant analysis, we identified proteins that clearly distinguish four SCLC subtypes based on their expression pattern, including potential diagnostic markers for SCLC-Y (e.g. GPX8, PKD2 and UFO) | ||
| 520 | |a CONCLUSIONS: We report for the first time, the protein expression differences among SCLC subtypes. By shedding light on potential subtype-specific therapeutic vulnerabilities and diagnostic biomarkers, our results may contribute to a better understanding of SCLC biology and the development of novel therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a diagnostic biomarkers | |
| 650 | 4 | |a molecular targets | |
| 650 | 4 | |a proteomics | |
| 650 | 4 | |a secretome | |
| 650 | 4 | |a small-cell lung cancer | |
| 650 | 4 | |a subtype | |
| 650 | 4 | |a transcriptomics | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Culture Media |2 NLM | |
| 650 | 7 | |a Nerve Growth Factors |2 NLM | |
| 650 | 7 | |a GPX8 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.11.1.- |2 NLM | |
| 650 | 7 | |a Peroxidases |2 NLM | |
| 650 | 7 | |a EC 1.11.1.- |2 NLM | |
| 700 | 1 | |a Megyesfalvi, Zsolt |e verfasserin |4 aut | |
| 700 | 1 | |a Woldmar, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Valkó, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Schwendenwein, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Bárány, Nándor |e verfasserin |4 aut | |
| 700 | 1 | |a Paku, Sándor |e verfasserin |4 aut | |
| 700 | 1 | |a László, Viktória |e verfasserin |4 aut | |
| 700 | 1 | |a Kiss, Helga |e verfasserin |4 aut | |
| 700 | 1 | |a Bugyik, Edina |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Szász, Attila Marcell |e verfasserin |4 aut | |
| 700 | 1 | |a Pizzatti, Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a Bogos, Krisztina |e verfasserin |4 aut | |
| 700 | 1 | |a Hoda, Mir Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Hoetzenecker, Konrad |e verfasserin |4 aut | |
| 700 | 1 | |a Marko-Varga, György |e verfasserin |4 aut | |
| 700 | 1 | |a Horvatovich, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Döme, Balázs |e verfasserin |4 aut | |
| 700 | 1 | |a Schelch, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Rezeli, Melinda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational medicine |d 2012 |g 12(2022), 9 vom: 18. Sept., Seite e1060 |w (DE-627)NLM224642685 |x 2001-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:9 |g day:18 |g month:09 |g pages:e1060 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ctm2.1060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 9 |b 18 |c 09 |h e1060 | ||